Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.31 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23717041 | 0.92 | POLB (0.38) | ADORA2APOLB | |
| SCHEMBL23717088 | 0.88 | SLC5A7 (0.36) | SLC5A7 | |
| SCHEMBL23674687 | 0.86 | AR (0.34) | ARPOLBIRAK4 | |
| SCHEMBL23674688 | 0.86 | AR (0.34) | ARPOLBIRAK4 | |
| SCHEMBL23674686 | 0.86 | AR (0.34) | ARPOLBIRAK4 | |
| SCHEMBL23674673 | 0.84 | AR (0.34) | AR | |
| SCHEMBL23717123 | 0.84 | AR (0.34) | AR | |
| SCHEMBL23674671 | 0.84 | AR (0.34) | AR | |
| SCHEMBL23717125 | 0.84 | AR (0.34) | AR | |
| SCHEMBL23674674 | 0.84 | AR (0.34) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11420976-B2 | Heterocyclic compounds as anti-viral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20210238188-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238188-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | VIP, ACE, FURIN | AR 4623/4885ADORA2A 1689/4885POLB 3294/4885 |
| US-11420976-B2 | Heterocyclic compounds as anti-viral agents | VIP, ACE, FURIN | AR 4623/4885ADORA2A 1689/4885POLB 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.